GlassScriptPhysician profile
Blake D Christensen
NPI 1841425477
$5,749.84
in general payments reported to CMS, 2019-2025
30 companies · $227 in 2025
The $227 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,597 · 2020: $1,117 · 2021: $795 · 2022: $355 · 2023: $386 · 2024: $273 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $885.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,938.96 | 2019-2021 | |
| Nevro Corp. | $1,264.91 | 2019-2024 | Senza |
| Vertiflex, INC. | $854.16 | 2019 | |
| Medtronic, INC. | $358.28 | 2021-2025 | Osteocool Rf Ablation System, Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Boston Scientific Corporation | $197.88 | 2020-2025 | Cre Pro |
| Globus Medical, INC. | $161.60 | 2025 | Senza, Omnia, Vyrsa V1 |
| Collegium Pharmaceutical, INC. | $130.76 | 2019-2023 | Belbuca |
| Biodelivery Sciences International, INC. | $116.94 | 2019-2021 | |
| Stryker Corporation | $85.48 | 2019-2020 | |
| Saluda Medical Americas, INC. | $74.24 | 2023-2025 | Evoke Scs, Evoke |
| Horizon Therapeutics Plc | $64.87 | 2019-2021 | |
| Assertio Therapeutics, INC. | $43.33 | 2019 | |
| Scilex Pharmaceuticals INC. | $39.27 | 2021 | |
| Sentynl Therapeutics, INC. | $38.88 | 2019 | |
| Medtronic USA, INC. | $37.64 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $33.77 | 2022-2024 | Nalu Neurostimulation System |
| Almatica Pharma LLC | $28.56 | 2021 | |
| Abbvie INC. | $28.52 | 2021 | |
| Virtus Pharmaceuticals LLC | $28.44 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $27.18 | 2021 | |
| Zyla Life Sciences, INC. | $27.00 | 2019 | |
| Pfizer INC. | $26.71 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.25 | 2019 | |
| Janssen Biotech, INC. | $21.92 | 2023 | Simponi Aria, Remicade |
| Amgen INC. | $20.78 | 2020 | |
| Bioventus LLC | $19.22 | 2022 | |
| Ucb, INC. | $16.93 | 2025 | Bimzelx |
| Spinal Simplicity, LLC | $14.58 | 2021 | |
| Stimwave Technologies Incorporated | $13.93 | 2021 | |
| Allergan, INC. | $12.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blake Christensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.